The study of fosaprepitant in the prevention of chemotherapy induced nausea and vomiting in patients with gynecologic cancer undergoing the combination therapy of Taxens and carboplatin.
Phase 2
- Conditions
- Cervical cancer, Endometrial cancer, Ovarian cancer, Fallopian tube cancer, and peritoneal cancer
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)The patient who is complicated with a serious liver damage or a renal damage. 2)A pregnant woman and the patient who may be pregnant now. 3)A patient with past hypersensitivity of fosaprepitant and/or ingredient of aprepitant. 4)A patient using Pimozide. 5)A patient using steroids. 6)Patients who were determined unsuitable for this study by medical doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the proportion of the patients with a complete response (CR, which was defined as no episodes of vomiting and no rescue therapy for nausea).
- Secondary Outcome Measures
Name Time Method